Representative engagement
CREATE Medicines / Myeloid Therapeutics
CREATE Medicines, formerly Myeloid Therapeutics, is a clinical-stage biotechnology company advancing in vivo CAR programs through first-in-human development.
- Challenge
- The organization needed translational and biomarker strategies that could connect complex platform science with clinical execution across research, clinical development, regulatory, clinical operations, manufacturing, bioanalytics, and external partners.
- Strategic Premise
- Translational strategy and biomarkers would connect platform science, patient evidence, and cross-functional execution across first-in-human clinical development.
- Michael's Role
- Senior Director, Translational Science. Michael led biomarker strategy and translational execution for MT302 and directed cross-functional startup of multinational Phase I program MT303.
- Technology and Execution Context
- In vivo CAR, translational medicine, clinical biomarkers, bioanalytics, precision medicine, and first-in-human clinical development.
- Outcome
- Michael's translational work supported full enrollment of MT302 in under 12 months. MT303 expanded the clinical pipeline and international operating footprint.
Timeline
Clinical execution
MT302 and MT303 Phase I programs
Michael connected translational strategy with coordinated clinical delivery across two first-in-human programs.